{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:37:20Z","timestamp":1792442240192,"version":"4.5.0"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Non-anticoagulant heparins (NAHs) are modified derivatives of heparin that retain many of the biological activities of the parent compound while exhibiting reduced or absent anticoagulant effects. These modifications have unlocked new therapeutic potentials in various diseases, including inflammatory disorders, cancer, sepsis, and viral infections. This review explores the chemical modifications of NAHs, their mechanisms of action, structure-activity relationships, and therapeutic applications. NAHs exert anti-inflammatory, anticancer, antiviral, and vascular protective effects by interacting with key proteins like heparanase, P-selectin, and HMGB1. Furthermore, their application in drug delivery systems, such as hydrogels and nanoparticles, enhances localized therapeutic efficacy. The promising results from preclinical and clinical studies position NAHs as a valuable class of drugs with diverse therapeutic applications, particularly in oncology, infectious diseases, and critical care.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1855688","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:48Z","timestamp":1784612148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications"],"prefix":"10.3389","volume":"17","author":[{"given":"Yaner","family":"Gu","sequence":"first","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fang","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiting","family":"Hong","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shams Ul","family":"Hassan","sequence":"additional","affiliation":[{"name":"School of Food and Medicine, Zhejiang Ocean University","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Food and Medicine, Zhejiang Ocean University","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhoushan Maternal and Child Care Hospital","place":["Zhoushan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13555","article-title":"A century of heparin: past, present and future","volume":"14","author":"Hemker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2021.103300","article-title":"Heparin beyond anti-coagulation","volume":"69","author":"Chen","year":"2021","journal-title":"Curr Res Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s42452-024-05802-8","article-title":"Role and mechanism of heparin in cardiovascular system","volume":"7","author":"Yu","year":"2025","journal-title":"Discover Appl Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(16)12001-7","article-title":"Heparin centenary - an ever-young life-saving drug","author":"Torri","year":"2016","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","author":"Cassinelli","year":"2016","journal-title":"Int J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.798088","article-title":"Prevention of triglyceridemia by (non-)anticoagulant heparin(oids) does not preclude transplant vasculopathy and glomerulosclerosis","volume":"10","author":"Shrestha","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119818","article-title":"Heparin: An old drug for new clinical applications","volume":"295","author":"Wang","year":"2022","journal-title":"Carbohydr Polym"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515221","article-title":"Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo","volume":"123","author":"Poli","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22040598","article-title":"Non-anticoagulant heparins are hepcidin antagonists for the treatment of anemia","volume":"22","author":"Poli","year":"2017","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14933","article-title":"Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910524","article-title":"Heparin and its derivatives: Challenges and advances in therapeutic biomolecules","volume":"22","author":"Banik","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272393","article-title":"Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia","volume":"107","author":"Abdulmalik","year":"2022","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.12.090","article-title":"Non-anticoagulant heparin derivatives for COVID-19 treatment","volume":"226","author":"Cao","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pgr2.70005","article-title":"Targeting heparanase\/heparan sulfate proteoglycans by non\u2010anticoagulant heparins: opportunities for innovative therapeutic approaches in sarcomas","volume":"2","author":"Lanzi","year":"2024","journal-title":"Proteoglycan Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101362","article-title":"Multifaceted heparin: diverse applications beyond anticoagulant therapy","volume":"17","author":"Sultana","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/0929867330666230203124032","article-title":"Research progress on antiviral activity of heparin","volume":"31","author":"Wang","year":"2024","journal-title":"Curr Med Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.148054","article-title":"Multifaceted roles of heparin and its derivatives in inflammation and cancer: mechanisms, clinical applications, and future directions","volume":"330","author":"Zeng","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.carbpol.2014.10.054","article-title":"Combinatorial one-pot chemoenzymatic synthesis of heparin","volume":"122","author":"Bhaskar","year":"2015","journal-title":"Carbohydr Polym"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.011","article-title":"Advances in the preparation and synthesis of heparin and related products","volume":"25","author":"Baytas","year":"2020","journal-title":"Drug Discov Today"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600307","article-title":"Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung","volume":"86","author":"Ono","year":"2002","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.9b00425","article-title":"Non-anticoagulant heparin as a pre-exposure prophylaxis prevents Lyme disease infection","volume":"6","author":"Lin","year":"2020","journal-title":"ACS Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(89)90442-8","article-title":"Partially N-desulfated heparin as a non-anticoagulant heparin: some physico-chemical and biological properties","volume":"55","author":"Sache","year":"1989","journal-title":"Thromb Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.053835","article-title":"Heparin\/heparan sulfate N-sulfamidase from Flavobacterium heparinum: structural and biochemical investigation of catalytic nitrogen-sulfur bond cleavage","volume":"284","author":"Myette","year":"2009","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpta.2026.101087","article-title":"Controllable polysaccharide depolymerization by heparinases for efficient low molecular weight heparin production","volume":"13","author":"Yang","year":"2026","journal-title":"Carbohydr Polym Technol Appl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/pl00012403","article-title":"N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo","volume":"51","author":"Wan","year":"2002","journal-title":"Inflammation Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-013-7446-4","article-title":"Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments","volume":"406","author":"Alekseeva","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.121834","article-title":"Improving impact of heparan sulfate on the endothelial glycocalyx abnormalities in atherosclerosis as revealed by glycan-protein interactome","volume":"330","author":"Chen","year":"2024","journal-title":"Carbohydr Polym"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22A","DOI":"10.1002\/0471142727.mb1722as32","article-title":"Nitrous acid degradation of glycosaminoglycans","volume":"17","author":"Conrad","year":"2001","journal-title":"Curr Protoc Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091254","article-title":"Non-anticoagulant activities of low molecular weight heparins-a review","volume":"16","author":"Feng","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00341","article-title":"Recombinant heparin-new opportunities","volume":"5","author":"Glass","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2020.121270","article-title":"Recent advances in biotechnology for heparin and heparan sulfate analysis","volume":"219","author":"Qiao","year":"2020","journal-title":"Talanta"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6215(02)00229-x","article-title":"Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site","volume":"337","author":"Islam","year":"2002","journal-title":"Carbohydr Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.11.023","article-title":"Structural analysis of heparin-derived 3-O-sulfated tetrasaccharides: antithrombin binding site variants","volume":"106","author":"Chen","year":"2017","journal-title":"J Pharm Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01551","article-title":"Non-anticoagulant low molecular weight heparins for pharmaceutical applications","volume":"62","author":"Ouyang","year":"2019","journal-title":"J Med Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116625","article-title":"State-of-the-art chromatographic and mass spectrometric techniques in heparin structural analysis","volume":"255","author":"Ouyang","year":"2025","journal-title":"J Pharm BioMed Anal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23501","article-title":"Structural characterization of pharmaceutical heparins prepared from different animal tissues","volume":"102","author":"Fu","year":"2013","journal-title":"J Pharm Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.07.004","article-title":"Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs","volume":"19","author":"Santos","year":"2014","journal-title":"Drug Discov Today"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.007","article-title":"Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties","volume":"54","author":"Tang","year":"2021","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.117232","article-title":"Comprehensive landscape of heparin therapy for COVID-19","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr Polym"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040584","article-title":"Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease","volume":"16","author":"Shute","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495260","article-title":"Heparin in sepsis: current clinical findings and possible mechanisms","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00483","article-title":"Targeting chemokine-glycosaminoglycan interactions to inhibit inflammation","volume":"11","author":"Crijns","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cyto.2014.12.010","article-title":"Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages","volume":"72","author":"Li","year":"2015","journal-title":"Cytokine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1160\/th06-05-0289","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb Haemost"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2803","article-title":"Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models","volume":"46","author":"Alyahya","year":"2015","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwu119","article-title":"Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: effect on P-selectin, heparanase, metastasis and cellular recruitment","volume":"25","author":"Gomes","year":"2015","journal-title":"Glycobiology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.12.213","article-title":"N-desulfated and reacetylated modification of heparin modulates macrophage polarization","volume":"229","author":"Zhu","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-514984","article-title":"Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis","volume":"123","author":"Wildhagen","year":"2014","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12398386","article-title":"Heparin and its non-anticoagulant analogues inhibit human keratinocyte growth without inducing differentiation","volume":"103","author":"Pillai","year":"1994","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antiviral Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5671","article-title":"Characterization of the heparin-binding properties of IL-6","volume":"165","author":"Mummery","year":"2000","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00283.x","article-title":"Regulation of interleukin-8 binding and function by heparin and \u03b12-macroglobulin","volume":"28","author":"Ramdin","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2002-0084OC","article-title":"Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue","volume":"28","author":"Frevert","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1998.0831","article-title":"Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins","volume":"30","author":"Kouretas","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115412","article-title":"Non-anticoagulant heparin alleviates myocardial ischemia-reperfusion injury through inhibiting GSDMD-mediated cardiomyocyte pyroptosis via the HMGB1\/RAGE pathway","volume":"165","author":"Wang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1021\/jm201708h","article-title":"Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis","volume":"55","author":"Ferro","year":"2012","journal-title":"J Med Chem"},{"key":"B62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-anticoagulant heparins as heparanase inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2016.09.032","article-title":"Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat","volume":"156","author":"Alekseeva","year":"2017","journal-title":"Carbohydr Polym"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414217200","article-title":"Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting","volume":"280","author":"Naggi","year":"2005","journal-title":"J Biol Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cww003","article-title":"Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase","volume":"26","author":"Pala","year":"2016","journal-title":"Glycobiology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00009.2010","article-title":"Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands","volume":"299","author":"Rao","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2017.03.036","article-title":"Heparin depolymerization by immobilized heparinase: A review","volume":"99","author":"Bhushan","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2021.100097","article-title":"Heparanase as active player in endothelial glycocalyx remodeling","volume":"13","author":"Masola","year":"2022","journal-title":"Matrix Biol Plus"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.898592","article-title":"Endothelial glycocalyx degradation in critical illness and injury","volume":"9","author":"Patterson","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.11.3253.3253","article-title":"Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation","volume":"82","author":"Nelson","year":"1993","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"FASEB J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.11589","article-title":"P-selectin-mediated adhesion between platelets and tumor cells promotes intestinal tumorigenesis in Apc(Min\/+) mice","volume":"11","author":"Qi","year":"2015","journal-title":"Int J Biol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-05-0332","article-title":"Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches","volume":"100","author":"Fritzsche","year":"2008","journal-title":"Thromb Haemost"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-01-0061","article-title":"Binding between heparin and the integrin VLA-4","volume":"102","author":"Schlesinger","year":"2009","journal-title":"Thromb Haemost"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-02-0158","article-title":"Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4","volume":"110","author":"Schmitz","year":"2013","journal-title":"Thromb Haemost"},{"key":"B76","doi-asserted-by":"publisher","first-page":"676731","DOI":"10.1155\/2012\/676731","article-title":"Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins","volume":"2012","author":"Bendas","year":"2012","journal-title":"Int J Cell Biol"},{"key":"B77","doi-asserted-by":"crossref","first-page":"chapter 11","DOI":"10.1007\/978-3-030-34521-1_11","article-title":"Heparanase in cancer metastasis \u2014 heparin as a potential inhibitor of cell adhesion molecules","volume-title":"Heparanase \u2014 From Basic Research to Clinical Applications","author":"Bendas","year":"2020"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9545-x","article-title":"Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis","volume":"34","author":"Schlesinger","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-020-00920-3","article-title":"High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic Malignancies","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020271","article-title":"Heparin, heparan sulphate and sepsis: potential new options for treatment","volume":"16","author":"Hogwood","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.013","article-title":"Beyond host defense: emerging functions of the immune system in regulating complex tissue physiology","volume":"173","author":"Rankin","year":"2018","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666191113113110","article-title":"The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer","volume":"27","author":"Yang","year":"2020","journal-title":"Curr Med Chem"},{"key":"B83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","article-title":"Low molecular weight heparins and their clinical applications","volume":"163","author":"Hao","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1177\/0885066621992320","article-title":"The role of histones and heparin in sepsis: a review","volume":"37","author":"Zhang","year":"2022","journal-title":"J Intensive Care Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.337","article-title":"Release and activity of histone in diseases","volume":"5","author":"Chen","year":"2014","journal-title":"Cell Death Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1151174","article-title":"Interactions of heparin with key glycoproteins of human respiratory syncytial virus","volume":"10","author":"Shi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2023.11.1067","article-title":"The role of heparin in spike SARS-CoV-2 infection: from a model for heparan sulfates to a starting structure for antivirals","volume":"123","author":"Paiardi","year":"2024","journal-title":"Biophys J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: Structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173634","article-title":"Heparins are potent inhibitors of ectonucleotide pyrophosphatase\/phosphodiesterase-1 (NPP1) \u2013 a promising target for the immunotherapy of cancer","volume":"14","author":"Lopez","year":"2023","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421699112","article-title":"Human caspase-4 mediates noncanonical inflammasome activation against gram-negative bacterial pathogens","volume":"112","author":"Casson","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B91","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12967-018-1621-5","article-title":"Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4\/signal transducer and activator of transcription 6\/Janus kinase 1 pathway","volume":"16","author":"Ghonim","year":"2018","journal-title":"J Transl Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00676-7","article-title":"Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury","volume":"43","author":"Deng","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B93","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.carbpol.2016.12.037","article-title":"Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: a review","volume":"160","author":"Yan","year":"2017","journal-title":"Carbohydr Polym"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.10.023","article-title":"The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives","volume":"129","author":"Schlesinger","year":"2012","journal-title":"Thromb Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-023-01576-4","article-title":"Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions","volume":"8","author":"Ji","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s13205-023-03719-4","article-title":"Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis","volume":"13","author":"Vimalraj","year":"2023","journal-title":"3 Biotech"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: a review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adh Migr"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins. Experimental\u00a0evidence","author":"Borsig","year":"2010","journal-title":"Thromb Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173778","article-title":"Review: Inhibitory potential of low molecular weight heparin in cell adhesion; emphasis on tumor metastasis","volume":"892","author":"Ejaz","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34521-1_32","article-title":"Heparanase, heparan sulfate and viral infection","volume":"1221","author":"Agelidis","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s1054-3589(08)60471-8","article-title":"Heparin in inflammation: potential therapeutic applications beyond anticoagulation","volume":"46","author":"Tyrrell","year":"1999","journal-title":"Adv Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2005.05.013","article-title":"Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans","volume":"12","author":"Noti","year":"2005","journal-title":"Chem Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1509","article-title":"Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins: Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents","volume":"101","author":"Koenig","year":"1998","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(24)36816-8","article-title":"Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung","volume":"282","author":"Fryer","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2174\/138161207781039742","article-title":"Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate","volume":"13","author":"Vlodavsky","year":"2007","journal-title":"Curr Pharm Des"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.118052","article-title":"Synthetic glycol-split heparin tri- and tetrasaccharides provide new insights into structural peculiarities for antiheparanase activity","volume":"118","author":"Ni","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.116824","article-title":"A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions","volume":"249","author":"Ji","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4409","article-title":"Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis","volume":"6","author":"Duckworth","year":"2015","journal-title":"Oncotarget"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-017-9774-7","article-title":"Structural and activity variability of fractions with different charge density and chain length from pharmaceutical heparins","volume":"34","author":"Yu","year":"2017","journal-title":"Glycoconj J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br J Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-642-23056-1_12","article-title":"Non-anticoagulant effects of heparin: an overview","volume":"2012","author":"Lever","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1157775","article-title":"Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1015-9584(09)60017-8","article-title":"Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study","volume":"32","author":"Lu","year":"2009","journal-title":"Asian J Surg"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111561","article-title":"Pharmacological and clinical application of heparin progress: an essential drug for modern medicine","volume":"139","author":"Qiu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B120","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000175157","article-title":"Non-anticoagulant heparins and inhibition of cancer","volume":"36","author":"Casu","year":"2008","journal-title":"Pathophysiol Haemost Thromb"},{"key":"B121","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2014.04.016","article-title":"Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin","volume":"350","author":"Sudha","year":"2014","journal-title":"Cancer Lett"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.12.022","article-title":"Thrombosis and cancer: 40 years of research","volume":"129","author":"Donati","year":"2012","journal-title":"Thromb Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101348","article-title":"A review of latest clinical practice guidelines for the management of cancer-associated thrombosis","volume":"35","author":"Frere","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34521-1_19","article-title":"PI-88 and related heparan sulfate mimetics","volume":"1221","author":"Chhabra","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0472","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase I results","volume":"22","author":"O\u2019Reilly","year":"2017","journal-title":"Oncologist"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7027","article-title":"CX-01, an inhibitor of CXCL12\/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS","volume":"36","author":"Huselton","year":"2018","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1398381","article-title":"Heparin-induced thrombocytopenia in critically ill patients","volume":"41","author":"Warkentin","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1303640","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s0142-9612(03)00557-x","article-title":"Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan\/non-anticoagulant heparin hydrogel","volume":"25","author":"Fujita","year":"2004","journal-title":"Biomaterials"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24244630","article-title":"Heparinoid complex-based heparin-binding cytokines and cell delivery carriers","volume":"24","author":"Ishihara","year":"2019","journal-title":"Molecules"},{"key":"B134","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bioactmat.2023.08.002","article-title":"Biomedical applications of engineered heparin-based materials","volume":"31","author":"Nazarzadeh Zare","year":"2024","journal-title":"Bioact Mater"},{"key":"B135","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00339-025-08593-w","article-title":"Heparinization of triple-layer electrospun PLA-COL@PLA-PCL@PCL-GEL small-caliber vascular scaffold with higher anticoagulant performance","volume":"131","author":"Chen","year":"2025","journal-title":"Appl Phys A"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/bc8003809","article-title":"Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity","volume":"20","author":"Wang","year":"2009","journal-title":"Bioconjug Chem"},{"key":"B137","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41467-024-50819-7","article-title":"Nano-anticoagulant based on carrier-free low molecular weight heparin and octadecylamine with an albumin shuttling effect","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201800409","article-title":"Non-anticoagulant heparin prodrug loaded biodegradable and injectable thermoresponsive hydrogels for enhanced anti-metastasis therapy","volume":"19","author":"Andrgie","year":"2019","journal-title":"Macromol Biosci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.11.005","article-title":"Bioreducible heparin-based nanogel drug delivery system","volume":"39","author":"Wu","year":"2015","journal-title":"Biomaterials"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160511785","article-title":"Biomedical application of low molecular weight heparin\/protamine nano\/micro particles as cell- and growth factor-carriers and coating matrix","volume":"16","author":"Ishihara","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.08.172","article-title":"Surface modification with hydrophilic and heparin-loaded coating for endothelialization and anticoagulation promotion of vascular scaffold","volume":"219","author":"Jiang","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2011.12.023","article-title":"Preservation of FGF-2 bioactivity using heparin-based nanoparticles, and their delivery from electrospun chitosan fibers","volume":"8","author":"Zomer Volpato","year":"2012","journal-title":"Acta Biomater"},{"key":"B143","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s44446-025-00022-6","article-title":"Emerging for non-invasive heparin delivery systems: recent advances, barriers, solutions, and applicability","volume":"33","author":"Albatsh","year":"2025","journal-title":"Saudi Pharm J"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200300640","article-title":"A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next","volume":"43","author":"Petitou","year":"2004","journal-title":"Angew Chem Int Ed Engl"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2017.09.012","article-title":"Synthetic heparin and heparan sulfate: probes in defining biological functions","volume":"40","author":"Tsai","year":"2017","journal-title":"Curr Opin Chem Biol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.01.006","article-title":"Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD","volume":"40","author":"Shute","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/med.20217","article-title":"Recent advances in search of oral heparin therapeutics","volume":"32","author":"Paliwal","year":"2012","journal-title":"Med Res Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:50Z","timestamp":1784612150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":148,"alternative-id":["10.3389\/fimmu.2026.1855688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1855688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1855688"}}